Chapter 15.Trazodone and Nefazodone
Sections
Excerpt
Trazodone was among the earliest “second generation” antidepressants to become available for clinical use in the United States in the early 1980s. Its side-effect profile and potential toxicity were considerably different from—and in many instances preferable to—those of the original antidepressants (i.e., the monoamine oxidase inhibitors [MAOIs] and tricyclic antidepressants [TCAs]). Several years later, trazodone’s pharmacological “cousin,” nefazodone, also became available.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
